McKesson Reports Fiscal 2012 Fourth-Quarter and Full-Year Results

April 30, 2012
  • Revenues of $31.7 billion for the fourth quarter and $122.7 billion for the full year.
  • Fourth-quarter GAAP earnings per diluted share of $2.09. Full-year GAAP earnings per diluted share from continuing operations of $5.59, up 30% year-over-year.
  • Fourth-quarter Adjusted Earnings per diluted share of $2.09. Full-year Adjusted Earnings per diluted share of $6.38, up 20% year-over-year.
  • Fiscal 2012 cash flow from operations of $2.9 billion.
  • Board of Directors authorized an additional $700 million share repurchase program.
  • Fiscal 2013 Outlook: Adjusted Earnings per diluted share of $7.05 to $7.35.

SAN FRANCISCO--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today reported that revenues for the fourth quarter ended March 31, 2012 were $31.7 billion, up 10% compared to $28.9 billion a year ago. On the basis of U.S. generally accepted accounting principles (“GAAP”), fourth-quarter earnings per diluted share was $2.09 compared to $1.62 a year ago.

For the fiscal year, McKesson had revenues of $122.7 billion compared to $112.1 billion a year ago. Full-year GAAP earnings per diluted share from continuing operations was $5.59 compared to $4.29 in the prior year.

McKesson separately reports financial results on the basis of Adjusted Earnings. Adjusted Earnings is a non-GAAP financial measure defined as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition-related expenses, and certain litigation reserve adjustments. A reconciliation of McKesson’s financial results determined in accordance with GAAP to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release.

Fourth-quarter Adjusted Earnings per diluted share was $2.09, up 17% compared to $1.78 a year ago. Full-year Adjusted Earnings per diluted share was $6.38, up 20% compared to $5.31 in the prior year.

“I am pleased with our fourth-quarter results led by solid execution in our Distribution Solutions businesses. For the full year, we had strong growth in both earnings and cash flow driven by our portfolio of solutions across healthcare,” said John H. Hammergren, chairman and chief executive officer.

During the fourth quarter, McKesson completed the acquisition of the independent banner and franchise businesses of Katz Group Canada Inc. for $919 million. Also during the fourth quarter, McKesson entered into an accelerated share repurchase agreement to buy $1.2 billion of its common stock.

For the year, McKesson generated cash from operations of $2.9 billion, and ended the year with cash and cash equivalents of $3.1 billion and a gross debt-to-capital ratio of 36.8%. During the year, McKesson repurchased $1.9 billion of common stock, spent $1.2 billion on acquisitions, paid $195 million in dividends, and had internal capital spending of $403 million.

At its most recent meeting, the Board of Directors authorized the repurchase of up to an additional $700 million of common stock, bringing the current total authorization to $1 billion.

“Our strong balance sheet and cash flow continue to provide us with opportunities to deploy capital to create value for our shareholders,” Hammergren commented. “Our acquisition of the Katz Group assets in our fiscal fourth quarter represents our largest international acquisition to date. The acquisition leverages the existing scale of our Canadian banner business and demonstrates our ongoing commitment to the health of the independent pharmacy. In addition, our continued strong cash flow allowed us to execute another accelerated share repurchase program in the fourth quarter. We plan to continue our portfolio approach to capital deployment with a mix of acquisitions, share repurchases, dividends, and internal investments.”

Segment Results

Distribution Solutions revenues were up 10% for the fourth quarter and 10% for the full year. U.S. pharmaceutical distribution revenues were up 10% for the fourth quarter, primarily reflecting new business with existing customers and market growth. For the full year, U.S. pharmaceutical distribution revenues also increased 10%, primarily reflecting market growth and the US Oncology acquisition.

Canadian revenues, on a constant currency basis, were up 13% for the fourth quarter primarily due to five additional sales days and market growth. Including the unfavorable currency impact of 1%, Canadian revenues increased 12% for the fourth quarter. For the full year, Canadian revenues grew 3% on a constant currency basis. Including the favorable currency impact of 2%, Canadian revenues grew 5% for the full year.

Medical-Surgical distribution and services revenues were up 8% for the fourth quarter and 8% for the full year, primarily driven by market growth and new customers.

In the fourth quarter, Distribution Solutions GAAP operating profit was $757 million and GAAP operating margin was 2.45%. Fourth-quarter adjusted operating profit was $792 million and the adjusted operating margin was 2.57%. For the full year, GAAP operating profit was $2.2 billion and GAAP operating margin was 1.86%. Full-year adjusted operating profit was $2.5 billion and the adjusted operating margin was 2.10%.

“Distribution Solutions had another excellent year with strong performance across the segment. Our U.S. pharmaceutical distribution business, in particular, continues to leverage its scale and comprehensive value proposition to deliver un-matched solutions to our customers. We were proud to have once again been selected by the Department of Veterans Affairs (VA) as its prime pharmaceutical supplier serving our nation’s veterans. We look forward to continuing to provide excellent service and value, and to meeting the VA’s growing needs over time,” said Hammergren.

In Technology Solutions, revenues were down 2% for the fourth quarter and up 4% for the full year. GAAP operating profit was $87 million for the fourth quarter and GAAP operating margin was 10.12%. Adjusted operating profit was $106 million for the fourth quarter and adjusted operating margin was 12.33%. For the full year, GAAP operating profit was $364 million and GAAP operating margin was 11.00%. Full-year adjusted operating profit was $440 million and the adjusted operating margin was 13.29%.

“I am pleased to see our Technology Solutions businesses working closely with our customers as they prepare for the requirements of Meaningful Use in the evolving landscape of healthcare IT regulation. As always, our top priority remains listening to our customers and providing solutions to help address their financial, clinical and integration requirements. We also continue to invest in our broad solution set for our payer, pharmacy and physician customers, and we continue to benefit from the stable and recurring nature of these revenue streams. We are committed to helping customers use IT strategically to enable better business, better care and better connectivity,” Hammergren said.

Fiscal Year 2013 Outlook

“We are pleased to provide Fiscal 2013 guidance that once again is expected to result in double-digit Adjusted Earnings per diluted share growth. McKesson expects Adjusted Earnings per diluted share between $7.05 and $7.35 for the fiscal year ending March 31, 2013,” Hammergren concluded.

Key Assumptions for Fiscal Year 2013 Outlook

The Fiscal 2013 outlook is based on the following key assumptions and is also subject to the Risk Factors outlined below.

  • Distribution Solutions revenue growth is expected to be at market rates, adjusted for our mix of business.
  • Branded and generic price trends in Fiscal 2013 are expected to be similar to those we experienced in Fiscal 2012. We expect strong growth in the contribution to profit from oral generic pharmaceuticals, but we expect profits from specialty generics will decline year-over-year.
  • Technology Solutions revenue growth should approximate the level of growth experienced in Fiscal 2012.
  • The guidance range assumes a full-year adjusted tax rate of 31%, which may vary from quarter to quarter.
  • Property acquisitions and capitalized software expenditures should be between $425 million and $475 million.
  • Cash flow from operations is expected to be between $2.0 and $2.5 billion.
  • Weighted average diluted shares used in the calculation of earnings are expected to be approximately 239 million for the year.
  • Based on acquisitions closed as of March 31, 2012:
    • We expect amortization of acquisition-related intangible assets of approximately 52 cents per diluted share.
    • We expect acquisition-related expenses of two cents per diluted share.
  • The Fiscal 2013 guidance range does not include any potential litigation reserve adjustments, or the impact of any potential new acquisitions, divestitures, impairments, or material restructuring or integration-related actions.

Risk Factors

Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: material adverse resolution of pending legal proceedings; changes in the U.S. healthcare industry and regulatory environment; changes in the Canadian healthcare industry and regulatory environment; competition; substantial defaults in payment or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or funding challenges; public health issues in the U.S. or abroad; implementation delay, malfunction, failure or breach of internal information systems; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others; system errors or failure of our technology products and solutions to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible assets; foreign currency fluctuations or disruptions to our foreign operations; new or revised tax legislation or challenges to our tax positions; the company’s ability to successfully identify, consummate and integrate strategic acquisitions; general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; and changes in accounting principles generally accepted in the United States of America. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

The company has scheduled a conference call for 5 PM ET. The dial-in number for individuals wishing to participate on the call is 719-234-7317. Erin Lampert, vice president, Investor Relations, is the leader of the call, and the password to join the call is ‘McKesson’. A replay of this conference call will be available for five calendar days. The dial-in number for individuals wishing to listen to the replay is 888-203-1112 and the passcode is 7490206. A webcast of the conference call will also be available live and archived on the company’s Investor Relations website at www.mckesson.com/investors.

Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website.

About McKesson

McKesson Corporation, currently ranked 15th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.

 

Schedule 1

 
McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS-GAAP

(unaudited)
(in millions, except per share amounts)
 
  Quarter Ended March 31,   Year Ended March 31,  
   
2012 2011

Change

2012 2011

Change

 
Revenues $ 31,699 $ 28,853 10 % $ 122,734 $ 112,084 10 %
 
Cost of sales (1) (2)   29,854     27,102   10   116,167     106,114   9
 
Gross profit 1,845 1,751 5 6,567 5,970 10
 

Operating expenses (1)

1,134 1,128 1 4,269 3,936 8

Litigation charges (3)

  4     -   -   149     213   (30 )

Total operating expenses

  1,138     1,128   1   4,418     4,149   6
 
Operating income 707 623 13 2,149 1,821 18
 
Other income (expense), net 9 17 (47 ) 21 36 (42 )
Interest expense   (59 )   (82 ) (28 )   (251 ) (222 ) 13
 
Income from continuing operations before income taxes 657 558 18 1,919 1,635 17
 
Income tax expense   (136 )   (136 ) -   (516 )   (505 ) 2
 
Income from continuing operations 521 422 23 1,403 1,130 24
 
Discontinued operation - gain on sale, net of tax (4) -     -   -   -     72   -
 
Net income $ 521   $ 422   23 $ 1,403   $ 1,202   17
 
Earnings per common share (5)
Diluted
Continuing operations $ 2.09 $ 1.62 29 % $ 5.59 $ 4.29 30 %

Discontinued operation - gain on sale

  -     -   -   -     0.28   -
Total $ 2.09   $ 1.62   29 $ 5.59   $ 4.57   22
 
Basic
Continuing operations $ 2.14 $ 1.65 30 % $ 5.70 $ 4.37 30 %
Discontinued operation - gain on sale   -     -   -   -     0.28   -
Total $ 2.14   $ 1.65   30 $ 5.70   $ 4.65   23
 
Shares on which earnings per common share were based
Diluted 249 260 (4 ) % 251 263 (5 ) %
Basic 244 255 (4 ) 246 258 (5 )
  (1)   Technology Solutions segment results for the fourth quarter and fiscal year 2012 include charges of $9 million and $51 million for a product alignment plan, of which $5 million and $31 million were included in cost of sales and $4 million and $20 million were included in operating expenses.
 
(2) Cost of sales for fiscal year 2011 includes an asset impairment charge of $72 million in our Technology Solutions segment for capitalized software held for sale and a credit of $51 million in our Distribution Solutions segment representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer.
 
(3) Represent charges for the Average Wholesale Price ("AWP") litigation.
 
(4) In fiscal year 2011 we sold a Technology Solutions business for $109 million of net sales proceeds. The after-tax gain on sale of $72 million has been recorded as a discontinued operation. Financial operating results for this business were immaterial.
 
(5) Certain computations may reflect rounding adjustments.
 

Schedule 2A

 
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
 
                      Change
Quarter Ended March 31, 2012 Vs. Prior Quarter

As Reported
(GAAP)

 

Amortization
of Acquisition-
Related
Intangibles

 

Acquisition-
Related
Expenses

 

Litigation
Reserve
Adjustments

 

Adjusted
Earnings
(Non-GAAP)

As
Reported
(GAAP)

 

Adjusted
Earnings
(Non-GAAP)

 
Revenues $ 31,699 $ - $ - $ - $ 31,699 10 % 10 %
 
Gross profit $ 1,845 $ 4 $ - $ - $ 1,849 5 5
Operating expenses (1,138 ) 40 5 4 (1,089 ) 1 2
Other income (expense), net 9 - - - 9 (47 ) 800
Interest expense   (59 )     -         -         -         (59 ) (28 ) (12 )
Income from continuing operations before income taxes 657 44 5 4 710 18 14
Income tax expense (1)   (136 )     (16 )       (2 )       (36 )       (190 ) - 18
Income from continuing operations $ 521     $ 28       $ 3       $ (32 )     $ 520   23 12
 

Diluted earnings per common share from continuing operations (2)

$ 2.09     $ 0.11       $ 0.02       $ (0.13 )     $ 2.09   29 % 17 %
Diluted weighted average shares   249       249         249         249         249   (4 ) % (4 ) %
 
 
Quarter Ended March 31, 2011

As Reported
(GAAP)

 

Amortization
of Acquisition-
Related
Intangibles

 

Acquisition-
Related
Expenses

 

Litigation
Reserve
Adjustments

 

Adjusted
Earnings
(Non-GAAP)

 
Revenues $ 28,853

 

$ - $ - $ - $ 28,853
 
Gross profit $ 1,751

 

$ 4 $ - $ - $ 1,755
Operating expenses (1,128 ) 44 19 - (1,065 )
Other income (expense), net 17 - (16 ) - 1
Interest expense   (82 )     -         15         -         (67 )
Income from continuing operations before income taxes 558 48 18 - 624
Income tax expense   (136 )     (18 )       (7 )       -         (161 )
Income from continuing operations $ 422     $ 30       $ 11       $ -       $ 463  

 

Diluted earnings per common share from continuing operations (2)

$ 1.62     $ 0.12       $ 0.04       $ -       $ 1.78  
Diluted weighted average shares   260       260         260         -         260  
  (1)   Litigation reserve adjustments includes a $34 million credit to income tax expense as a result of a reversal of an income tax reserve.
(2) Certain computations may reflect rounding adjustments.

Adjusted Earnings (Non-GAAP) Financial Information

 
Adjusted Earnings represents income from continuing operations, excluding the effects of the following items from the Company’s GAAP financial results, including the related income tax effects:
 

Amortization of acquisition-related intangibles - Amortization expense of acquired intangible assets purchased in connection with acquisitions by the Company.

 

Acquisition-related expenses - Transaction and integration expenses that are directly related to acquisitions by the Company. Examples include transaction closing costs, professional service fees, restructuring or severance charges, retention payments, employee relocation expenses, facility or other exit-related expenses, recoveries of acquisition-related expenses or post-closing expenses, or bridge loan fees.

 

Litigation reserve adjustments - Adjustments to the Company’s reserves, including accrued interest, for estimated probable losses for its Average Wholesale Price and Securities Litigation matters, as such terms were defined in the Company’s Annual Reports on Form 10-K for the fiscal years ended March 31, 2011 and 2009.

 
Income taxes on Adjusted Earnings are calculated in accordance with Accounting Standards Codification 740, “Income Taxes,” which is the same accounting principles used by the Company when presenting its GAAP financial results.
 
The Company believes the presentation of non-GAAP measures such as Adjusted Earnings provides useful supplemental information to investors with regard to its core operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Adjusted Earnings assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's Adjusted Earnings measure may be defined and calculated differently by other companies in the same industry.
 
The Company internally uses non-GAAP financial measures such as Adjusted Earnings in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. Nonetheless, non-GAAP financial results and related measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
 

Schedule 2B

 
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
 
            Change
Year Ended March 31, 2012 Vs. Prior Period

As Reported
(GAAP)

 

Amortization
of Acquisition-
Related
Intangibles

 

Acquisition-
Related
Expenses

 

Litigation
Reserve
Adjustments

 

Adjusted
Earnings
(Non-GAAP)

As
Reported
(GAAP)

 

Adjusted
Earnings
(Non-GAAP)

 
Revenues $ 122,734 $ - $ - $ - $ 122,734 10 % 10 %
 
Gross profit $ 6,567 $ 20 $ - $ - $ 6,587 10 10
Operating expenses (4,418 ) 171 31 149 (4,067 ) 6 8
Other income, net 21 - - - 21 (42 ) 5
Interest expense   (251 )     -       -       -       (251 ) 13 27
Income from continuing operations before income taxes 1,919 191 31 149 2,290 17 13
Income tax expense (1)   (516 )     (72 )     (11 )     (89 )     (688 ) 2 8
Income from continuing operations $ 1,403     $ 119     $ 20     $ 60     $ 1,602   24 15
 

Diluted earnings per common share from continuing operations (2)

$ 5.59     $ 0.47     $ 0.08     $ 0.24     $ 6.38   30 % 20 %
Diluted weighted average shares   251       251       251       251       251   (5 ) % (5 ) %
 
 
Year Ended March 31, 2011

As Reported
(GAAP)

 

Amortization
of Acquisition-
Related
Intangibles

 

Acquisition-
Related
Expenses

 

Litigation
Reserve
Adjustments

 

Adjusted
Earnings
(Non-GAAP)

 
Revenues $ 112,084

 

$ - $ - $ - $ 112,084
 
Gross profit $ 5,970

 

$ 16 $ - $ - $ 5,986
Operating expenses (4,149 ) 116 43 213 (3,777 )
Other income, net 36 - (16 ) - 20
Interest expense   (222 )     -       25       -       (197 )
Income from continuing operations before income taxes 1,635 132 52 213 2,032
Income tax expense   (505 )     (51 )     (16 )     (64 )     (636 )
Income from continuing operations $ 1,130     $ 81     $ 36     $ 149     $ 1,396  
 

Diluted earnings per common share from continuing operations (2)

$ 4.29     $ 0.31     $ 0.14     $ 0.57     $ 5.31  
Diluted weighted average shares   263       263       263       263       263  
  (1)   Litigation reserve adjustments includes a $31 million credit to income tax expense as a result of a reversal of an income tax reserve.
(2) Certain computations may reflect rounding adjustments.
 

Schedule 3A

 
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions)
 
  Quarter Ended March 31, 2012 Quarter Ended March 31, 2011 Change

As
Reported
(GAAP)

 

Adjustments

 

Adjusted
Earnings
(Non-
GAAP)

As
Reported
(GAAP)

 

Adjustments

 

Adjusted
Earnings
(Non-
GAAP)

As
Reported
(GAAP)

 

Adjusted
Earnings

(Non-
GAAP)

REVENUES    
Distribution Solutions
Direct distribution & services $ 22,039 $ - $ 22,039 $ 20,460 $ - $ 20,460 8 % 8 %
Sales to customers' warehouses   5,455       -       5,455     4,498       -       4,498   21 21

Total U.S. pharmaceutical distribution & services

27,494 - 27,494 24,958 - 24,958 10 10
Canada pharmaceutical distribution & services 2,564 - 2,564 2,299 - 2,299 12 12
Medical-Surgical distribution & services   781       -       781     720       -       720   8 8
Total Distribution Solutions   30,839       -       30,839     27,977       -       27,977   10 10
 
Technology Solutions
Services 678 - 678 656 - 656 3 3
Software & software systems 147 - 147 181 - 181 (19 ) (19 )
Hardware   35       -       35     39       -       39   (10 ) (10 )
Total Technology Solutions   860       -       860     876       -       876   (2 ) (2 )
Revenues $ 31,699     $ -     $ 31,699   $ 28,853     $ -     $ 28,853   10 10
 
GROSS PROFIT
Distribution Solutions $ 1,467 $ - $ 1,467 $ 1,326 $ - $ 1,326 11 11
Technology Solutions (1)   378       4       382     425       4       429   (11 ) (11 )
Gross profit $ 1,845     $ 4     $ 1,849   $ 1,751     $ 4     $ 1,755   5 5
 
OPERATING EXPENSES
Distribution Solutions $ (718 ) $ 35 $ (683 ) $ (710 ) $ 49 $ (661 ) 1 3
Technology Solutions (1) (294 ) 15 (279 ) (310 ) 12 (298 ) (5 ) (6 )
Corporate   (126 )     (1 )     (127 )   (108 )     2       (106 ) 17 20
Operating expenses $ (1,138 )   $ 49     $ (1,089 ) $ (1,128 )   $ 63     $ (1,065 ) 1 2
 
OTHER INCOME (EXPENSE), NET
Distribution Solutions $ 8 $ - $ 8 $ (4 ) $ - $ (4 ) (300 ) (300 )
Technology Solutions 3 - 3 2 - 2 50 50
Corporate   (2 )     -       (2 )   19       (16 )     3   (111 ) (167 )
Other income (expense), net $ 9     $ -     $ 9   $ 17     $ (16 )   $ 1   (47 ) 800
 
OPERATING PROFIT
Distribution Solutions $ 757 $ 35 $ 792 $ 612 $ 49 $ 661 24 20
Technology Solutions (1)   87       19       106     117       16       133   (26 ) (20 )
Operating profit 844 54 898 729 65 794 16 13
Corporate   (128 )     (1 )     (129 )   (89 )     (14 )     (103 ) 44 25

Income from continuing operations before interest expense and income taxes

$ 716     $ 53     $ 769   $ 640     $ 51     $ 691   12 11
 
STATISTICS
Operating profit as a % of revenues
Distribution Solutions 2.45 % 2.57 % 2.19 % 2.36 % 26 bp 21 bp
Technology Solutions (1) 10.12 12.33 13.36 15.18 (324 ) (285 )
  (1)   For the fourth quarter of fiscal year 2012, segment results, as reported under US GAAP and Adjusted Earnings, include a charge of $9 million for a product alignment plan, of which $5 million and $4 million were included in cost of sales and operating expenses.
 

Schedule 3B

 
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions)
 
  Year Ended March 31, 2012 Year Ended March 31, 2011 Change

As
Reported
(GAAP)

  Adjustments  

Adjusted
Earnings
(Non-
GAAP)

As
Reported
(GAAP)

  Adjustments  

Adjusted
Earnings
(Non-
GAAP)

As
Reported
(GAAP)

 

Adjusted
Earnings
(Non-
GAAP)

REVENUES    
Distribution Solutions
Direct distribution & services $ 85,523 $ - $ 85,523 $ 77,554 $ - $ 77,554 10 % 10 %
Sales to customers' warehouses   20,453       -       20,453     18,631       -       18,631   10 10

Total U.S. pharmaceutical distribution & services

105,976 - 105,976 96,185 - 96,185 10 10
Canada pharmaceutical distribution & services 10,303 - 10,303 9,784 - 9,784 5 5
Medical-Surgical distribution & services   3,145       -       3,145     2,920       -       2,920   8 8
Total Distribution Solutions   119,424       -       119,424     108,889       -       108,889   10 10
 
Technology Solutions
Services 2,594 - 2,594 2,483 - 2,483 4 4
Software & software systems 596 - 596 590 - 590 1 1
Hardware   120       -       120     122       -       122   (2 ) (2 )
Total Technology Solutions   3,310       -       3,310     3,195       -       3,195   4 4
Revenues $ 122,734     $ -     $ 122,734   $ 112,084     $ -     $ 112,084   10 10
 
GROSS PROFIT
Distribution Solutions (2) $ 5,057 $ 1 $ 5,058 $ 4,565 $ - $ 4,565 11 11
Technology Solutions (1) (3)   1,510       19       1,529     1,405       16       1,421   7 8
Gross profit $ 6,567     $ 20     $ 6,587   $ 5,970     $ 16     $ 5,986   10 10
 
OPERATING EXPENSES
Distribution Solutions $ (2,854 ) $ 293 $ (2,561 ) $ (2,673 ) $ 324 $ (2,349 ) 7 9
Technology Solutions (1) (1,151 ) 57 (1,094 ) (1,108 ) 46 (1,062 ) 4 3
Corporate   (413 )     1       (412 )   (368 )     2       (366 ) 12 13
Operating expenses $ (4,418 )   $ 351     $ (4,067 ) $ (4,149 )   $ 372     $ (3,777 ) 6 8
 
OTHER INCOME, NET
Distribution Solutions $ 16 $ - $ 16 $ 5 $ - $ 5 220 220
Technology Solutions 5 - 5 4 - 4 25 25
Corporate   -       -       -     27       (16 )     11   (100 ) (100 )
Other income, net $ 21     $ -     $ 21   $ 36     $ (16 )   $ 20   (42 ) 5
 
OPERATING PROFIT
Distribution Solutions (2) $ 2,219 $ 294 $ 2,513 $ 1,897 $ 324 $ 2,221 17 13
Technology Solutions (1) (3)   364       76       440     301       62       363   21 21
Operating profit 2,583 370 2,953 2,198 386 2,584 18 14
Corporate   (413 )     1       (412 )   (341 )     (14 )     (355 ) 21 16

Income from continuing operations before interest expense and income taxes

$ 2,170     $ 371     $ 2,541   $ 1,857     $ 372     $ 2,229   17 14
 
STATISTICS
Operating profit as a % of revenues
Distribution Solutions (2) 1.86 % 2.10 % 1.74 % 2.04 % 12 bp 6 bp
Technology Solutions (1) (3) 11.00 13.29 9.42 11.36 158 193
Results under US GAAP and Adjusted Earnings, include the following:
   
(1) For fiscal year 2012, results include a charge of $51 million for a product alignment plan, of which $31 million and $20 million were included in cost of sales and operating expenses.
 
(2) Results for fiscal year 2011 include a credit of $51 million representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer.
 
(3) Results for fiscal year 2011 include a $72 million asset impairment charge for capitalized software held for sale.
 

Schedule 4A

 
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE
(unaudited)
(in millions)
 
 
  Quarter Ended March 31, 2012   Quarter Ended March 31, 2011

Distribution
Solutions

 

Technology
Solutions

 

Corporate
& Interest
Expense

 

Total

Distribution
Solutions

 

Technology
Solutions

 

Corporate
& Interest
Expense

  Total

As Reported (GAAP):

           
Revenues $ 30,839 $ 860 $ - $ 31,699 $ 27,977 $ 876 $ - $ 28,853
 
Gross profit $ 1,467 $ 378 $ - $ 1,845 $ 1,326 $ 425 $ - $ 1,751
Operating expenses (718 ) (294 ) (126 ) (1,138 ) (710 ) (310 ) (108 ) (1,128 )
Other income (expense), net   8       3       (2 )     9     (4 )     2       19       17  

Income from continuing operations before interest expense and income taxes

757 87 (128 ) 716 612 117 (89 ) 640
Interest expense   -       -       (59 )     (59 )   (1 )     -       (81 )     (82 )
Income from continuing operations before income taxes $ 757     $ 87     $ (187 )   $ 657   $ 611     $ 117     $ (170 )   $ 558  
 

Pre-Tax Adjustments:

Gross profit $ - $ 4 $ - $ 4 $ - $ 4 $ - $ 4
Operating expenses   27       13       -       40     32       12       -       44  
Amortization of acquisition-related intangibles 27 17 - 44 32 16 - 48
 
Operating expenses 4 2 (1 ) 5 17 - 2 19
Other income, net - - - - - - (16 ) (16 )
Interest expense   -       -       -       -     -       -       15       15  
Acquisition-related expenses 4 2 (1 ) 5 17 - 1 18
 
Operating expenses - Litigation reserve adjustments 4 - - 4 - - - -
                           
Total pre-tax adjustments $ 35     $ 19     $ (1 )   $ 53   $ 49     $ 16     $ 1     $ 66  
 

Adjusted Earnings (Non-GAAP):

Revenues $ 30,839 $ 860 $ - $ 31,699 $ 27,977 $ 876 $ - $ 28,853
 
Gross profit $ 1,467 $ 382 $ - $ 1,849 $ 1,326 $ 429 $ - $ 1,755
Operating expenses (683 ) (279 ) (127 ) (1,089 ) (661 ) (298 ) (106 ) (1,065 )
Other income (expense), net   8       3       (2 )     9     (4 )     2       3       1  

Income from continuing operations before interest expense and income taxes

792 106 (129 ) 769 661 133 (103 ) 691
Interest expense   -       -       (59 )     (59 )   (1 )     -       (66 )     (67 )
Income from continuing operations before income taxes $ 792     $ 106     $ (188 )   $ 710   $ 660     $ 133     $ (169 )   $ 624  
 

Schedule 4B

               
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE
(unaudited)
(in millions)
 
 
Year Ended March 31, 2012 Year Ended March 31, 2011

Distribution
Solutions

 

Technology
Solutions

 

Corporate
& Interest
Expense

 

Total

Distribution
Solutions

 

Technology
Solutions

 

Corporate
& Interest
Expense

  Total

As Reported (GAAP):

Revenues $ 119,424 $ 3,310 $ - $ 122,734 $ 108,889 $ 3,195 $ - $ 112,084
 
Gross profit $ 5,057 $ 1,510 $ - $ 6,567 $ 4,565 $ 1,405 $ - $ 5,970
Operating expenses (2,854 ) (1,151 ) (413 ) (4,418 ) (2,673 ) (1,108 ) (368 ) (4,149 )
Other income, net   16       5       -       21     5       4       27       36  

Income from continuing operations before interest expense and income taxes

2,219 364 (413 ) 2,170 1,897 301 (341 ) 1,857
Interest expense   -       -       (251 )     (251 )   (1 )     -       (221 )     (222 )
Income from continuing operations before income taxes $ 2,219     $ 364     $ (664 )   $ 1,919   $ 1,896     $ 301     $ (562 )   $ 1,635  
 

Pre-Tax Adjustments:

Gross profit $ 1 $ 19 $ - $ 20 $ - $ 16 $ - $ 16
Operating expenses   120       51       -       171     70       46       -       116  
Amortization of acquisition-related intangibles 121 70 - 191 70 62 - 132
 
Operating expenses 24 6 1 31 41 - 2 43
Other income (expense), net - - - - - - (16 ) (16 )
Interest expense   -       -       -       -     -       -       25       25  
Acquisition-related expenses 24 6 1 31 41 - 11 52
 
Operating expenses - Litigation reserve adjustments 149 - - 149 213 - - 213
                           
Total pre-tax adjustments $ 294     $ 76     $ 1     $ 371   $ 324     $ 62     $ 11     $ 397  
 

Adjusted Earnings (Non-GAAP):

Revenues $ 119,424 $ 3,310 $ - $ 122,734 $ 108,889 $ 3,195 $ - $ 112,084
 
Gross profit $ 5,058 $ 1,529 $ - $ 6,587 $ 4,565 $ 1,421 $ - $ 5,986
Operating expenses (2,561 ) (1,094 ) (412 ) (4,067 ) (2,349 ) (1,062 ) (366 ) (3,777 )
Other income, net   16       5       -       21     5       4       11       20  

Income from continuing operations before interest expense and income taxes

2,513 440 (412 ) 2,541 2,221 363 (355 ) 2,229
Interest expense   -       -       (251 )     (251 )   (1 )     -       (196 )     (197 )
Income from continuing operations before income taxes $ 2,513     $ 440     $ (663 )   $ 2,290   $ 2,220     $ 363     $ (551 )   $ 2,032  
 

Schedule 5

 
McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)
 
    March 31,   March 31,

2012

2011
 
ASSETS
Current Assets
Cash and cash equivalents $ 3,149 $ 3,612
Receivables, net 9,977 9,187
Inventories, net 10,073 9,225

Prepaid expenses and other

  404   333
Total Current Assets 23,603 22,357
Property, Plant and Equipment, Net 1,043 991
Goodwill 5,032 4,364
Intangible Assets, Net 1,750 1,456
Other Assets   1,665   1,718
Total Assets $ 33,093 $ 30,886
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Drafts and accounts payable $ 16,114 $ 14,090
Short-term borrowings 400 -
Deferred revenue 1,423 1,321
Deferred tax liabilities 1,092 1,037
Current portion of long-term debt 508 417
Other accrued liabilities   2,149   1,861
Total Current Liabilities 21,686 18,726
Long-Term Debt 3,072 3,587
Other Noncurrent Liabilities 1,504 1,353
Stockholders' Equity   6,831   7,220
Total Liabilities and Stockholders' Equity $ 33,093 $ 30,886
 

Schedule 6

 
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)
 
  Year Ended March 31,
2012   2011
 
 
OPERATING ACTIVITIES
Net income $ 1,403 $ 1,202
Discontinued operation – gain on sale, net of tax - (72 )
Adjustments to reconcile to net cash provided by operating activities:
Depreciation and amortization 551 496
Asset impairment charge - capitalized software held for sale - 72
Deferred taxes 242 184
Share-based compensation expense 154 137
Other non-cash items 96 30
Changes in operating assets and liabilities, net of acquisitions:
Receivables (770 ) (673 )
Inventories (878 ) 367
Drafts and accounts payable 2,027 533
Litigation charges 149 213
Litigation settlement payments (26 ) (26 )
Deferred tax benefit on litigation charges (78 ) (56 )
Other   80     (69 )
Net cash provided by operating activities   2,950     2,338  
 
INVESTING ACTIVITIES
Property acquisitions (225 ) (233 )
Capitalized software expenditures (178 ) (155 )
Acquisitions, less cash and cash equivalents acquired (1,156 ) (292 )
Proceeds from sale of business - 109
Other   57     (53 )
Net cash used in investing activities   (1,502 )   (624 )
 
FINANCING ACTIVITIES
Proceeds from short-term borrowings 400 1,000
Repayments of short-term borrowings - (1,000 )
Proceeds from long-term borrowings - 1,689
Repayments of long-term debt (430 ) (1,730 )
Common stock repurchases, including shares surrendered for tax withholding (1,874 ) (2,050 )
Common stock Issuances 167 367
Dividends paid (195 ) (171 )
Other   27     54  
Net cash used in financing activities   (1,905 )   (1,841 )
Effect of exchange rate changes on cash and cash equivalents   (6 )   8  
Net decrease in cash and cash equivalents (463 ) (119 )
Cash and cash equivalents at beginning of period   3,612     3,731  
Cash and cash equivalents at end of period $ 3,149   $ 3,612  
 

Contact:

McKesson Corporation
Erin Lampert, 415-983-8391 (Investors and Financial Media)
Erin.Lampert@McKesson.com
Kris Fortner, 415-983-8352 (General and Business Media)
Kris.Fortner@McKesson.com